<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307134</url>
  </required_header>
  <id_info>
    <org_study_id>B1931027</org_study_id>
    <nct_id>NCT04307134</nct_id>
  </id_info>
  <brief_title>Besponsa Post Marketing Surveillance Study</brief_title>
  <official_title>Korean Post Marketing Surveillance Study to Observe Safety and Effectiveness of BESPONSA (REGISTERED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Besponsa is approved for the treatment of R/R B-cell ALL in Korea. In accordance with the&#xD;
      Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing&#xD;
      surveillance is required to determine any problems or questions associated with besponsa&#xD;
      after marketing in Korea, with regard to the following clauses under conditions of general&#xD;
      clinical practice. Therefore, through this study, effectiveness and safety of besponsa will&#xD;
      be observed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the approval of BESPONSA速 in Korea, this non-interventional study is designated as a&#xD;
      Post-Marketing Surveillance (PMS) Study and is a commitment to Ministry of Food and Drug&#xD;
      Safety (MFDS), as a part of Risk Management Plan (RMP) which is required by MFDS. The safety&#xD;
      and effectiveness information of BESPONSA速 will be gathered at minimum 160 subjects&#xD;
      administered in the setting of routine practice in Korea during the initial 6 years after the&#xD;
      approval.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">April 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events categorized according to physical organ and disease/symptom</measure>
    <time_frame>28 days following the last administration of BESPONSA速.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hematologic Maligmancy</condition>
  <arm_group>
    <arm_group_label>R/R ALL</arm_group_label>
    <description>Patients diagnosed as relapsed or refractory B-cell precursor lymphoblastic leukemia (ALL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotuzumab ozogamicin</intervention_name>
    <description>R/R ALL who treated with Inotuzumab ozogamicin</description>
    <arm_group_label>R/R ALL</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed as relapsed or refractory B-cell precursor lymphoblastic leukemia (ALL).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible for inclusion in&#xD;
        the study:&#xD;
&#xD;
          1. Patients diagnosed as relapsed or refractory B-cell precursor lymphoblastic leukemia&#xD;
             (ALL).&#xD;
&#xD;
          2. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the patient (or a legally acceptable representative) has been informed of all&#xD;
             pertinent aspects of the study.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Patients meeting any of the following criteria will not be included in the study:&#xD;
&#xD;
          1. Any patients who does not agree that Pfizer and companies working with Pfizer use&#xD;
             his/her information.&#xD;
&#xD;
          2. Patients to whom BESPONSA速 is contraindicated as per the local labeling.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B1931027</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory and relapsed B-cell ALL</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inotuzumab Ozogamicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

